Literature DB >> 33872285

Multistage Rectal Polypectomy: An Alternative to Proctectomy in Patients with Familial Adenomatous Polyposis.

Joshua Sommovilla1, David Liska, James Church.   

Abstract

INTRODUCTION: When patients with familial adenomatous polyposis have a severely affected rectum it is usually assumed that endoscopic control is impossible or unwise. The standard approach is proctectomy with either an end ileostomy, or an ileal pouch anal anastomosis. Here we show that application of aggressive, multistage snare polypectomy to this situation can be effective and allow the patient to avoid surgery, at least in the short term. TECHNIQUE: Standard polypectomy using snare excision with coagulation is used, taking two or three sessions, and beginning with the largest polyps. The procedures are done with the patient under general anesthesia. Endoscopic mucosal resection technique with fluid injection to lift polyps is not necessary.
RESULTS: Complete control of the rectal polyps, sustained for at least 2 years, is possible without functional sequelae.
CONCLUSIONS: Familial adenomatous polyposis patients with severe rectal polyposis can be offered multistage rectal polypectomy and safely avoid proctectomy.IRB and consent approval through the David G Jagelman Inherited Colorectal Cancer Registry.
Copyright © 2021 The American Society of Colon and Rectal Surgeons.

Entities:  

Year:  2021        PMID: 33872285     DOI: 10.1097/DCR.0000000000002030

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  1 in total

1.  Prevalence and Management of Cancer of the Rectal Stump after Total Colectomy and Rectal Sparing in Patients with Familial Polyposis: Results from a Registry-Based Study.

Authors:  Gaia Colletti; Chiara Maura Ciniselli; Stefano Signoroni; Ivana Maria Francesca Cocco; Andrea Magarotto; Maria Teresa Ricci; Clorinda Brignola; Clara Bagatin; Laura Cattaneo; Andrea Mancini; Federica Cavalcoli; Massimo Milione; Paolo Verderio; Marco Vitellaro
Journal:  Cancers (Basel)       Date:  2022-01-08       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.